Welcome to our dedicated page for Accuray Incorporated news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorporated stock.
Accuray Incorporated (NASDAQ: ARAY) is a pioneering radiation oncology company dedicated to advancing precise, innovative tumor treatment solutions. Headquartered in Madison, Wisconsin, Accuray develops, manufactures, and markets cutting-edge technology designed to deliver a full spectrum of radiation therapy and radiosurgery treatments. Their flagship products, such as the CyberKnife® and Radixact® Systems, set new standards in cancer treatment by offering unparalleled precision and real-time tumor tracking capabilities.
The CyberKnife® System utilizes a non-invasive robotic platform to treat various types of cancer and tumors throughout the body. This system excels through its ability to track, detect, and correct for tumor and patient movement in real-time during procedures, enhancing the accuracy of radiation delivery. This unique approach ensures high-dose radiation is administered with sub-millimeter precision, allowing patients to breathe normally without manual intervention.
Accuray's recent achievements include significant milestones in product development and market expansion. In October 2023, the company announced the Chinese National Medical Products Administration's approval of the CNNC-Accuray joint venture Tomo® C radiation therapy system. This system, tailored for the Chinese Type B market, aims to expand access to radiotherapy treatments, addressing the country's growing demand for cancer care solutions.
Financially, Accuray has demonstrated robust performance. According to their first-quarter fiscal 2024 report, the company achieved a total net revenue of $103.9 million, reflecting a year-over-year increase. Despite a net loss of $3.0 million, the company reported a significant improvement in gross profit margins, emphasizing its strategic focus on revenue growth and operational efficiency.
Accuray remains committed to continuous innovation. The launch of the VitalHold™ package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan highlights their ongoing efforts to enhance treatment options. This feature enables deep inspiration breath hold (DIBH) treatments, particularly for breast cancer, thereby improving patient outcomes and reducing treatment-associated stress.
The company's dedication to excellence is further exemplified by its recent partnerships and educational initiatives. In April 2024, Accuray opened a new training center in Genolier, Switzerland, which serves as a European hub for advanced radiosurgery and radiotherapy training. This facility aims to elevate the skills and knowledge of medical professionals, ensuring the delivery of high-quality, precise treatments.
Accuray's vision of transforming patient care is evident in their continuous pursuit of technological advancements and strategic collaborations. Their products not only enhance the precision and effectiveness of cancer treatments but also contribute to improved patient quality of life post-treatment. With a strong commitment to innovation, Accuray is well-positioned to lead the radiation therapy industry into the future.
Accuray Incorporated (NASDAQ: ARAY) announced CE Mark certification for its ClearRT™ helical fan-beam kVCT imaging technology, enhancing the Radixact® System. This approval allows distribution in the EU, US, Japan, and other regions. ClearRT offers integrated imaging for precise radiation therapy, improving the treatment of tumors. It promises benefits like increased patient throughput and high-fidelity imaging. The technology is expected to support the growing demand for stereotactic body radiation therapy (SBRT), which requires advanced accuracy in treatment delivery.
Accuray Incorporated (NASDAQ: ARAY) announced a new five-year $80 million term loan and $40 million revolving credit facility with Silicon Valley Bank. The New Credit Facility aims to refinance existing debts and will provide working capital and operational flexibility. Borrowings will have a floating interest rate between 2.50% and 3.25%, significantly lower than previous margins. This move enhances their capital structure and reduces borrowing costs, allowing for better liquidity to support business growth.
Accuray Incorporated (NASDAQ: ARAY) announced a significant financial move on May 6, 2021, by entering into agreements to exchange $82.1 million of existing 3.75% senior convertible notes due 2022 for $97.1 million of new 3.75% senior convertible notes due 2026. Additionally, the company will sell $2.9 million of new notes for cash. The transactions, expected to close around May 13, 2021, will allow Accuray to repurchase approximately 3.1 million shares of its common stock at $4.51 per share. The new notes feature a conversion rate of 170.5611 shares per $1,000 principal, representing a 30% premium over the last stock price.
Accuray Incorporated (NASDAQ: ARAY) has announced the granting of equity inducement awards to Dr. Jean-Philippe Pignol, its new Chief Medical & Technology Officer. As part of his induction, Dr. Pignol received 53,191 restricted stock units and a stock option for 96,480 shares, effective April 30, 2021. The stock option has a ten-year term with an exercise price of $4.70. Vesting of the awards will occur annually and monthly, contingent upon Dr. Pignol's continued service. These inducement awards comply with NASDAQ Listing Rule 5635(c)(4) and are consistent with the 2016 Equity Incentive Plan.
Geisinger has become the first hospital system in the U.S. to implement Accuray's Synchrony technology on its CyberKnife® S7™ and Radixact® Systems for advanced cancer care. This initiative aims to enhance the targeting of radiation therapy while minimizing damage to healthy tissue. Synchrony utilizes AI for real-time radiation adjustments based on tumor movement, leading to more efficient treatment. Geisinger's investment is part of their expansion at the Henry Cancer Center, where hypofractionated radiotherapy is now possible, offering higher doses with greater precision.
Accuray announced that its customers secured the top two spots in the MArkerless Lung Target Tracking CHallenge (MATCH) using the Synchrony technology on the Radixact and CyberKnife systems. The challenge evaluated the accuracy of tumor-tracking algorithms, with scoring based on radiation therapy system precision. Accuray's technology allows real-time adaptation of treatment based on patient movement, improving treatment accuracy and patient comfort. The results demonstrate Synchrony's potential to enhance lung cancer therapy, offering a non-invasive option for medically inoperable patients.
Accuray Incorporated (NASDAQ: ARAY) reported Q3 fiscal 2021 results, with net revenue of $102.6 million, up from $99.5 million year-over-year. System revenue in China amounted to $24.9 million, while gross orders were $87.4 million, a 16% increase from Q2. However, net loss stood at $0.4 million, a substantial decline from a net income of $2.6 million in the same quarter last year. The company also received regulatory approval for its ClearRT™ Helical kVCT Imaging in Japan. Cash reserves increased to $130.1 million.
Accuray Incorporated (NASDAQ: ARAY) has announced that its ClearRT helical fan-beam kVCT imaging system has been in clinical use for over two months, demonstrating significant potential in radiation oncology. The first patient treatments at Willis-Knighton Cancer Center show enhanced imaging quality, allowing for superior tumor visualization and treatment precision. ClearRT has received Shonin approval in Japan and FDA 510(k) clearance, with a CE Mark expected by the end of June 2021, expanding its market accessibility. The first commercial ClearRT systems have been shipped as scheduled.
Accuray Incorporated (NASDAQ: ARAY) will release its third-quarter financial results for fiscal year 2021, ending March 31, 2021, on April 27, 2021, post-market. The management will hold a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Dial-in numbers are provided for participants, and a live webcast will be available through the company's Investor Relations website. Accuray focuses on innovative radiation therapy solutions aimed at enhancing patient care.
Accuray Incorporated (NASDAQ: ARAY) will participate in the Cowen Annual Health Care Conference on March 2, 2021, at 11:50 AM Pacific. The event is an invitation-only conference connecting over 325 health care companies with institutional investors, focusing on investment opportunities and sector trends. A live webcast of the Fireside Chat will be available on Accuray's website. Accuray is dedicated to innovating radiation therapy solutions to improve patient outcomes across oncology and neuro-radiosurgery.
FAQ
What is the current stock price of Accuray Incorporated (ARAY)?
What is the market cap of Accuray Incorporated (ARAY)?
What is Accuray Incorporated's primary focus?
What are the flagship products of Accuray?
What recent achievements has Accuray announced?
How has Accuray performed financially in recent quarters?
What is the significance of the CyberKnife® System?
How does Accuray support medical professionals?
What is the goal of the VitalHold™ package?
How does Accuray contribute to global cancer treatment?
Where is Accuray headquartered?
What is the strategic vision of Accuray?
